Loading…
A rationale for targeting the P2X7 receptor in Coronavirus disease 19
Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activa...
Saved in:
| Published in: | British journal of pharmacology 2020-11, Vol.177 (21), p.4990-4994 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3 |
| container_end_page | 4994 |
| container_issue | 21 |
| container_start_page | 4990 |
| container_title | British journal of pharmacology |
| container_volume | 177 |
| creator | Di Virgilio, Francesco Tang, Yong Sarti, Alba Clara Rossato, Marco |
| description | Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid‐19‐associated severe pneumonia.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc |
| doi_str_mv | 10.1111/bph.15138 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280564</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451916460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3</originalsourceid><addsrcrecordid>eNp1kU1PGzEQhq2qqAmhh_4BZKmXctjg2fXa3gsSjfiSkOBApd4srzObGG3Wwd6l4t_XIRABEnOZw_v40cgvIT-ATSHNcb1eTqGEQn0hY-BSZGWh4CsZM8ZkBqDUiOzHeM9YCmX5jYyKnHOQqhiTs1MaTO98Z1qkjQ-0N2GBvesWtF8ivc3_ShrQ4rpPmevozIfEProwRDp3EU1ECtUB2WtMG_H7y56QP-dnd7PL7Prm4mp2ep1ZzguVocmtFVUFWDV1o4xUlpVsDtCAlBWWVS64BSxEzSHPwdaqTg9rVpVCGKNMMSEnW-96qFc4t9j1wbR6HdzKhCftjdPvk84t9cI_apkrVgqeBL9eBME_DBh7vXLRYtuaDv0Qdc6ZKJhSbIP-_IDe-yGkf9pQJVQguGCJOtpSNvgYAza7Y4DpTTk6laOfy0ns4dvrd-RrGwk43gL_XItPn5v079vLrfI_etyXdQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451916460</pqid></control><display><type>article</type><title>A rationale for targeting the P2X7 receptor in Coronavirus disease 19</title><source>PubMed (Medline)</source><source>Wiley-Blackwell Read & Publish Collection</source><creator>Di Virgilio, Francesco ; Tang, Yong ; Sarti, Alba Clara ; Rossato, Marco</creator><creatorcontrib>Di Virgilio, Francesco ; Tang, Yong ; Sarti, Alba Clara ; Rossato, Marco</creatorcontrib><description>Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid‐19‐associated severe pneumonia.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15138</identifier><identifier>PMID: 32441783</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; Betacoronavirus - isolation & purification ; Coronavirus Infections - drug therapy ; Coronavirus Infections - physiopathology ; Coronavirus Infections - virology ; Coronaviruses ; COVID-19 ; Cytokine Release Syndrome - virology ; Cytokine storm ; Cytokines ; Edema ; Humans ; Inflammation ; Lymphocytes T ; Macrophages ; Macrophages - pathology ; Morbidity ; Pandemics ; Pneumonia ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - physiopathology ; Pneumonia, Viral - virology ; Receptors, Purinergic P2X7 - drug effects ; Receptors, Purinergic P2X7 - metabolism ; Research Paper ; Respiratory distress syndrome ; Respiratory Distress Syndrome - drug therapy ; Respiratory Distress Syndrome - virology ; SARS-CoV-2 ; T-Lymphocytes - pathology ; Themed Issue: Research Paper</subject><ispartof>British journal of pharmacology, 2020-11, Vol.177 (21), p.4990-4994</ispartof><rights>2020 The British Pharmacological Society</rights><rights>2020 The British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3</citedby><cites>FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3</cites><orcidid>0000-0002-2543-066X ; 0000-0002-2371-3359 ; 0000-0003-4327-2500 ; 0000-0003-3566-1362</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280564/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280564/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32441783$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Virgilio, Francesco</creatorcontrib><creatorcontrib>Tang, Yong</creatorcontrib><creatorcontrib>Sarti, Alba Clara</creatorcontrib><creatorcontrib>Rossato, Marco</creatorcontrib><title>A rationale for targeting the P2X7 receptor in Coronavirus disease 19</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid‐19‐associated severe pneumonia.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><subject>Animals</subject><subject>Betacoronavirus - isolation & purification</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - physiopathology</subject><subject>Coronavirus Infections - virology</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Cytokine Release Syndrome - virology</subject><subject>Cytokine storm</subject><subject>Cytokines</subject><subject>Edema</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Lymphocytes T</subject><subject>Macrophages</subject><subject>Macrophages - pathology</subject><subject>Morbidity</subject><subject>Pandemics</subject><subject>Pneumonia</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - physiopathology</subject><subject>Pneumonia, Viral - virology</subject><subject>Receptors, Purinergic P2X7 - drug effects</subject><subject>Receptors, Purinergic P2X7 - metabolism</subject><subject>Research Paper</subject><subject>Respiratory distress syndrome</subject><subject>Respiratory Distress Syndrome - drug therapy</subject><subject>Respiratory Distress Syndrome - virology</subject><subject>SARS-CoV-2</subject><subject>T-Lymphocytes - pathology</subject><subject>Themed Issue: Research Paper</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kU1PGzEQhq2qqAmhh_4BZKmXctjg2fXa3gsSjfiSkOBApd4srzObGG3Wwd6l4t_XIRABEnOZw_v40cgvIT-ATSHNcb1eTqGEQn0hY-BSZGWh4CsZM8ZkBqDUiOzHeM9YCmX5jYyKnHOQqhiTs1MaTO98Z1qkjQ-0N2GBvesWtF8ivc3_ShrQ4rpPmevozIfEProwRDp3EU1ECtUB2WtMG_H7y56QP-dnd7PL7Prm4mp2ep1ZzguVocmtFVUFWDV1o4xUlpVsDtCAlBWWVS64BSxEzSHPwdaqTg9rVpVCGKNMMSEnW-96qFc4t9j1wbR6HdzKhCftjdPvk84t9cI_apkrVgqeBL9eBME_DBh7vXLRYtuaDv0Qdc6ZKJhSbIP-_IDe-yGkf9pQJVQguGCJOtpSNvgYAza7Y4DpTTk6laOfy0ns4dvrd-RrGwk43gL_XItPn5v079vLrfI_etyXdQ</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Di Virgilio, Francesco</creator><creator>Tang, Yong</creator><creator>Sarti, Alba Clara</creator><creator>Rossato, Marco</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2543-066X</orcidid><orcidid>https://orcid.org/0000-0002-2371-3359</orcidid><orcidid>https://orcid.org/0000-0003-4327-2500</orcidid><orcidid>https://orcid.org/0000-0003-3566-1362</orcidid></search><sort><creationdate>202011</creationdate><title>A rationale for targeting the P2X7 receptor in Coronavirus disease 19</title><author>Di Virgilio, Francesco ; Tang, Yong ; Sarti, Alba Clara ; Rossato, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Betacoronavirus - isolation & purification</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - physiopathology</topic><topic>Coronavirus Infections - virology</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Cytokine Release Syndrome - virology</topic><topic>Cytokine storm</topic><topic>Cytokines</topic><topic>Edema</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Lymphocytes T</topic><topic>Macrophages</topic><topic>Macrophages - pathology</topic><topic>Morbidity</topic><topic>Pandemics</topic><topic>Pneumonia</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - physiopathology</topic><topic>Pneumonia, Viral - virology</topic><topic>Receptors, Purinergic P2X7 - drug effects</topic><topic>Receptors, Purinergic P2X7 - metabolism</topic><topic>Research Paper</topic><topic>Respiratory distress syndrome</topic><topic>Respiratory Distress Syndrome - drug therapy</topic><topic>Respiratory Distress Syndrome - virology</topic><topic>SARS-CoV-2</topic><topic>T-Lymphocytes - pathology</topic><topic>Themed Issue: Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Virgilio, Francesco</creatorcontrib><creatorcontrib>Tang, Yong</creatorcontrib><creatorcontrib>Sarti, Alba Clara</creatorcontrib><creatorcontrib>Rossato, Marco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Virgilio, Francesco</au><au>Tang, Yong</au><au>Sarti, Alba Clara</au><au>Rossato, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A rationale for targeting the P2X7 receptor in Coronavirus disease 19</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>177</volume><issue>21</issue><spage>4990</spage><epage>4994</epage><pages>4990-4994</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid‐19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid‐19‐associated severe pneumonia.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32441783</pmid><doi>10.1111/bph.15138</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-2543-066X</orcidid><orcidid>https://orcid.org/0000-0002-2371-3359</orcidid><orcidid>https://orcid.org/0000-0003-4327-2500</orcidid><orcidid>https://orcid.org/0000-0003-3566-1362</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2020-11, Vol.177 (21), p.4990-4994 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7280564 |
| source | PubMed (Medline); Wiley-Blackwell Read & Publish Collection |
| subjects | Animals Betacoronavirus - isolation & purification Coronavirus Infections - drug therapy Coronavirus Infections - physiopathology Coronavirus Infections - virology Coronaviruses COVID-19 Cytokine Release Syndrome - virology Cytokine storm Cytokines Edema Humans Inflammation Lymphocytes T Macrophages Macrophages - pathology Morbidity Pandemics Pneumonia Pneumonia, Viral - drug therapy Pneumonia, Viral - physiopathology Pneumonia, Viral - virology Receptors, Purinergic P2X7 - drug effects Receptors, Purinergic P2X7 - metabolism Research Paper Respiratory distress syndrome Respiratory Distress Syndrome - drug therapy Respiratory Distress Syndrome - virology SARS-CoV-2 T-Lymphocytes - pathology Themed Issue: Research Paper |
| title | A rationale for targeting the P2X7 receptor in Coronavirus disease 19 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T23%3A32%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20rationale%20for%20targeting%20the%20P2X7%20receptor%20in%20Coronavirus%20disease%2019&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Di%20Virgilio,%20Francesco&rft.date=2020-11&rft.volume=177&rft.issue=21&rft.spage=4990&rft.epage=4994&rft.pages=4990-4994&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15138&rft_dat=%3Cproquest_pubme%3E2451916460%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4438-ea2cc6991e9fbf8a78c050d11f1779e59264c1e36b41221cb8bc44b09566aa8a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2451916460&rft_id=info:pmid/32441783&rfr_iscdi=true |